In collaboration with Robert Wood Johnson University Hospital, an RWJBarnabas Health facility, the Transplant and Cellular Therapy Program at Rutgers Cancer Institute has been performing autologous and allogeneic stem cell transplants since 1995. Ours is the only such program in New Jersey offered at an NCI-designated Comprehensive Cancer Center.
The program treats patients with a number of illnesses including acute and chronic leukemias, myelodysplasia, lymphomas, Hodgkin disease, multiple myeloma, amyloidosis, and others. Our oncologists are experts in Blood and Marrow Transplants (BMT), CAR T-Cell therapy, cellular therapy and more.
The clinical and research interests of our clinicians focus on novel strategies to prevent graft-versus-host disease, improve umbilical cord blood transplants, and develop cellular therapies that are less toxic than standard transplants.
The Transplant and Cellular Therapy Program is accredited by the National Marrow Donor Program and the Foundation for the Accreditation of Cellular Therapy (FACT). It has been rated “Excellent” by the American College of Surgeons. We offer a full suite of oncology support services through which Oncology Nurse Navigators and transplant coordinators guide patients through treatment and beyond. Rutgers Cancer Institute also offers stem cell transplantation for children, adolescents and young adults with cancers and blood disorders through our Pediatric Stem Cell Transplantation and Cellular Therapies Program.
To request an appointment, call 844-CANCERNJ | Find Cellular Therapy Clinical Trials.
Your Transplant and Cellular Therapy Team
- Chief, Section of Transplant and Cell Therapy, Rutgers Cancer Institute
- Chief of the Transplant and Cell Therapy Service of the RWJBarnabas Health Oncology Service Line
- Director for Cell Therapy and Bone Marrow Transplantation at Robert Wood Johnson University Hospital
- Professor of Medicine at Rutgers Robert Wood Johnson Medical School
- Hematologist/Oncologist
- Assistant Professor of Medicine, Rutgers Robert Wood Johnson Medical School
- Deputy Director for Clinical Services, Rutgers Cancer Institute;
- System Director of Medical Oncology and Oncology Lead, RWJBarnabas Health Medical Group
- Associate Vice Chancellor for Clinical Innovation and Data Analytics, Rutgers Biomedical and Health Sciences
- Hematologist/Oncologist
- Director of Cell Therapy and Bone Marrow Transplantation Northern Regions, RWJBarnabas Health
- Associate Professor of Medicine, Rutgers Robert Wood Johnson Medical School
- Hematologist/Oncologist
- Assistant Professor of Medicine, Rutgers Robert Wood Johnson Medical School
- Director of Myeloid Malignancies
- Professor of Medicine, Rutgers Robert Wood Johnson Medical School
- Hematologist/Oncologist
- Assistant Professor of Medicine, Rutgers Robert Wood Johnson Medical School
- Medical Director, Laurie Proton Therapy Center
- Radiation Oncologist
- Professor of Radiation Oncology, Rutgers Robert Wood Johnson Medical School
- Advanced Practice Nurse
- Advanced Practice Nurse
- Advanced Practice Nurse
- Advanced Practice Nurse, Proceduralists
- Advanced Practice Nurse
- Advanced Practice Provider
- Per Diem
- Advanced Practice Provider
- Advanced Practice Provider
- Advanced Practice Provider
- Advanced Practice Provider
- Inpatient
- Advanced Practice Provider
- Per Diem
- Advanced Practice Provider
- Advanced Practice Provider
- Per Diem
- BMT Coordinator
- BMT Coordinator
- BMT Coordinator
- Research
- Navigator
- Nutritionist
- Social Worker
East Tower
The Transplant and Cellular Therapy Program location:
Learn more about the East Tower Location
Related News
Transplant and Cell Therapy Program Awarded Accreditation by the Foundation for the Accreditation of Cellular Therapy
The Foundation for the Accreditation of Cellular Therapy (FACT) has once again awarded Rutgers Cancer Institute and Robert Wood Johnson University Hospital’s (RWJUH) Transplant and Cell Therapy Program accreditation under the FACT-JACIE International Standards for Hematopoietic Cellular Therapy.
Hematology/Oncology Data Showcase: 65th American Society of Hematology Annual Meeting and Exposition
Rutgers Cancer Institute and RWJBarnabas Health provide 36 oral and poster presentations that examine new advancements in the diagnosis, treatment, and management of blood cancers.
Why is CAR T-Cell Therapy So Exciting? Answers From an Expert
CAR T-cell immunotherapy is a cutting-edge treatment option for patients with adult aggressive B-cell non-Hodgkin lymphoma or acute lymphoblastic leukemia in children or young adults.
Leukemia and Transplant Team Collaboration
Neil Palmisiano, MD, MS discusses the collaboration process between teams when treating blood cancer patients using bone marrow transplants.
Hematology/Oncology Research at Rutgers Cancer Institute
Andrew Evens, DO, MBA, MSc discusses research advances in blood cancers and cellular therapy happening at Rutgers Cancer Institute.